When I learned that more than 30,000 women in California had joined, and that only 48 Black women in California—or African American women—had joined,… - Olufunmilayo Olopade

" "

When I learned that more than 30,000 women in California had joined, and that only 48 Black women in California—or African American women—had joined, that's when I said to Laura [Laura Esserman, MD, MBA, co-investigator and professor at UCSF], “This is unacceptable. You have to come to Chicago, and then we have to open this up nationwide so that an and then we have to open this up nationwide so that any woman who is going to get a mammogram can join.” For me, what I wanted to do is to bring it to the South Side of Chicago in a predominantly African American community, and we wanted to make sure that everyone in our community has a chance to join WISDOM if they wish to. We have found that when you ask women to participate, and they learn about the study, they sign up. And that's what I have learned since 2016. And the reason why women don't sign up for studies is because we didn't ask them, or we didn't make it easy for them to join. So I'm really looking forward to finding out with 100,000 women what's the safest and best factors to use to screen for breast cancer.

English
Collect this quote

About Olufunmilayo Olopade

Olufunmilayo Olopade (born 1957) is a Nigerian hematology oncologist, Associate Dean for Global Health and Walter L. Palmer Distinguished Service Professor in Medicine and Human Genetics at the University of Chicago. She also serves as director of the University of Chicago Hospital's Cancer Risk Clinic.

Also Known As

Alternative Names: Olufunmilayo I Olopade Olufunmilayo I. Olopade Funmi Olopade
PREMIUM FEATURE
Advanced Search Filters

Filter search results by source, date, and more with our premium search tools.

Related quotes. More quotes will automatically load as you scroll down, or you can use the load more buttons.

Additional quotes by Olufunmilayo Olopade

Unlimited Quote Collections

Organize your favorite quotes without limits. Create themed collections for every occasion with Premium.

Triple-negative breast cancer is not the majority of breast cancer. But if we have drugs that can target the genetic abnormalities in these tumors, and we are able to rapidly conduct global clinical trials, not only can we get studies done quickly, but we can also make it possible for women all over the world to participate in the cures of tomorrow.

Loading...